NCT04091685

Brief Summary

Knowing what will DMSA spect add to the DMSA planar in detection in renal cortical defects

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

September 13, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 17, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2020

Completed
Last Updated

September 17, 2019

Status Verified

September 1, 2019

Enrollment Period

1 year

First QC Date

September 13, 2019

Last Update Submit

September 13, 2019

Conditions

Dimercaptosuccinic Acid SPECT and Planar

Outcome Measures

Primary Outcomes (1)

  • Comparison between DMSA spect and planar imaging

    Analysis of DMSA spect and planar imaging to clarify early renal cortical defects

    Baseline

Secondary Outcomes (1)

  • Clarify added value of DMSA spect over planar

    Baseline

Interventions

Gamma camera imagingDEVICE

Use gamma camera in detection of renal cortical defects

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with history of peylo nephritis ,malrotated kidney ,ectopic kidney with no age limitation

You may qualify if:

  • patient with history of peylo nephritis.

You may not qualify if:

  • pregnant women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Radionuclide Imaging

Intervention Hierarchy (Ancestors)

Diagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, Radioisotope

Central Study Contacts

Marwa Sayed Mahamed

CONTACT

00201010573518marwasayed1599@gmail.com

Mohamed A Mekkawy, PhD

CONTACT

01223196777

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

September 13, 2019

First Posted

September 17, 2019

Study Start

September 1, 2019

Primary Completion

September 1, 2020

Study Completion

October 1, 2020

Last Updated

September 17, 2019

Record last verified: 2019-09